# Evidence Summary Table Template

**ç”¨é€”**: ç³»ç»ŸåŒ–æ±‡æ€»å’Œæ¯”è¾ƒå¤šé¡¹ç ”ç©¶çš„å…³é”®ä¿¡æ¯
**é€‚ç”¨åœºæ™¯**: æ²»ç–—æ–¹æ¡ˆæ¯”è¾ƒã€è¯ç‰©è¯„ä¼°ã€Meta-analysiså‡†å¤‡

---

## ğŸ“Š Evidence Summary Table

| Study | Design | Population | N | Intervention | Comparator | Primary Outcome | Effect Size | Evidence Level | Notes |
|-------|--------|------------|---|--------------|------------|-----------------|-------------|----------------|-------|
| [ç ”ç©¶åç§°/NCTå·] | [RCT/è§‚å¯Ÿæ€§/Meta] | [æ‚£è€…ç‰¹å¾] | [æ ·æœ¬é‡] | [å¹²é¢„æªæ–½] | [å¯¹ç…§ç»„] | [ä¸»è¦ç»ˆç‚¹] | [HR/OR/RR + 95%CI] | [Level 1-5] | [å…³é”®ä¿¡æ¯] |
| | | | | | | | | | |
| | | | | | | | | | |

---

## ğŸ“ å¡«å†™è¯´æ˜

### Studyï¼ˆç ”ç©¶æ ‡è¯†ï¼‰
**æ ¼å¼**: `ä½œè€…å et al. (å¹´ä»½)` æˆ– `NCTå·`
**ç¤ºä¾‹**:
- `Modi et al. NEJM 2020 (DESTINY-Breast01)`
- `NCT03529110`

### Designï¼ˆç ”ç©¶è®¾è®¡ï¼‰
**é€‰é¡¹**:
- `RCT` - éšæœºå¯¹ç…§è¯•éªŒ
- `Single-arm Phase II` - å•è‡‚IIæœŸ
- `Retrospective cohort` - å›é¡¾æ€§é˜Ÿåˆ—
- `Meta-analysis` - Metaåˆ†æ
- `Registry study` - æ³¨å†Œç™»è®°ç ”ç©¶

### Populationï¼ˆæ‚£è€…ç¾¤ä½“ï¼‰
**å…³é”®è¦ç´ **ï¼ˆç”¨ç®€æ´è¯­è¨€æè¿°ï¼‰:
- ç–¾ç—…ç±»å‹åŠåˆ†æœŸ
- å…³é”®ç”Ÿç‰©æ ‡å¿—ç‰©ï¼ˆå¦‚HER2+, EGFR mutï¼‰
- æ—¢å¾€æ²»ç–—çº¿æ•°
- ç‰¹æ®Šäººç¾¤ï¼ˆå¦‚è„‘è½¬ç§»ã€è€å¹´äººï¼‰

**ç¤ºä¾‹**:
- `HER2+ mBC, 2L+, æ—¢å¾€T-DM1æ²»ç–—`
- `EGFR exon19del/L858R NSCLC, 1L`

### Nï¼ˆæ ·æœ¬é‡ï¼‰
**æ ¼å¼**: ç›´æ¥å¡«å†™æ•°å­—
**æ³¨æ„**: å¦‚æœæœ‰å¤šä¸ªæ²»ç–—ç»„ï¼Œå¡«å†™æ€»æ ·æœ¬é‡

**ç¤ºä¾‹**:
- `184` (å•è‡‚ç ”ç©¶)
- `524 (262 vs 262)` (RCT)

### Interventionï¼ˆå¹²é¢„æªæ–½ï¼‰
**æ ¼å¼**: `è¯ç‰©å å‰‚é‡ ç»™è¯æ–¹æ¡ˆ`

**ç¤ºä¾‹**:
- `T-DXd 5.4mg/kg IV q3w`
- `Osimertinib 80mg PO QD`
- `Tucatinib 300mg PO BID + Capecitabine + Trastuzumab`

### Comparatorï¼ˆå¯¹ç…§ç»„ï¼‰
**æ ¼å¼**: åŒIntervention
**æ³¨æ„**: å•è‡‚ç ”ç©¶å¡«å†™ `N/A` æˆ– `Historical control`

**ç¤ºä¾‹**:
- `Physician's choice (T-DM1/Capecitabine+Trastuzumab/Lapatinib+Capecitabine)`
- `Placebo + BSC`

### Primary Outcomeï¼ˆä¸»è¦ç»ˆç‚¹ï¼‰
**å¸¸è§ç»ˆç‚¹ç¼©å†™**:
- `ORR` - å®¢è§‚ç¼“è§£ç‡
- `PFS` - æ— è¿›å±•ç”Ÿå­˜æœŸ
- `OS` - æ€»ç”Ÿå­˜æœŸ
- `pCR` - ç—…ç†å®Œå…¨ç¼“è§£ç‡
- `DFS` - æ— ç—…ç”Ÿå­˜æœŸ

**æ ¼å¼**: `ç»ˆç‚¹åç§° (å®šä¹‰)`

**ç¤ºä¾‹**:
- `ORR (CR+PR per RECIST 1.1)`
- `PFS (BICR)`
- `OS (death from any cause)`

### Effect Sizeï¼ˆæ•ˆåº”é‡ï¼‰
**æ ¼å¼å–å†³äºç»“å±€ç±»å‹**:

**äºŒåˆ†ç±»ç»“å±€ï¼ˆORR, pCRï¼‰**:
```
ORR: 60.9% vs 20.2% (p<0.001)
æˆ–
ORR: 60.9% (95% CI: 53.4-68.0)
```

**æ—¶é—´-äº‹ä»¶ç»“å±€ï¼ˆPFS, OSï¼‰**:
```
Median PFS: 16.8m vs 6.9m
HR 0.44 (95% CI: 0.36-0.55, p<0.001)
```

**è¿ç»­æ€§ç»“å±€**:
```
Mean change: -2.3 vs -0.8 (p=0.02)
```

### Evidence Levelï¼ˆè¯æ®ç­‰çº§ï¼‰
**ä½¿ç”¨Oxford CEBMæˆ–GRADEç³»ç»Ÿ**

**Oxford CEBM Levels**:
- `Level 1` - é«˜è´¨é‡RCTæˆ–ç³»ç»Ÿç»¼è¿°
- `Level 2` - è¾ƒä½è´¨é‡RCTæˆ–é«˜è´¨é‡è§‚å¯Ÿæ€§ç ”ç©¶
- `Level 3` - ç—…ä¾‹å¯¹ç…§ç ”ç©¶
- `Level 4` - ç—…ä¾‹ç³»åˆ—
- `Level 5` - ä¸“å®¶æ„è§

**GRADEåˆ†çº§** (å¯é€‰):
- `High` - é«˜è´¨é‡
- `Moderate` - ä¸­ç­‰è´¨é‡
- `Low` - ä½è´¨é‡
- `Very Low` - æä½è´¨é‡

### Notesï¼ˆå¤‡æ³¨ï¼‰
**è®°å½•å…³é”®ä¿¡æ¯**:
- ç ”ç©¶çš„ç‹¬ç‰¹ä¼˜åŠ¿
- é‡è¦çš„å±€é™æ€§
- äºšç»„åˆ†æå‘ç°
- å®‰å…¨æ€§ä¿¡å·

**ç¤ºä¾‹**:
- `è„‘è½¬ç§»äºšç»„: ORR 45.5% vs 33.3%`
- `Grade â‰¥3 AE: 45% (ä¸»è¦ä¸ºè¡€æ¶²å­¦æ¯’æ€§)`
- `ä¸­ä½éšè®¿æ—¶é—´ä»…8.2ä¸ªæœˆï¼ŒOSæ•°æ®ä¸æˆç†Ÿ`

---

## ğŸ’¡ ä½¿ç”¨ç¤ºä¾‹

### ç¤ºä¾‹1: HER2+ä¹³è…ºç™ŒäºŒçº¿æ²»ç–—æ¯”è¾ƒ

| Study | Design | Population | N | Intervention | Comparator | Primary Outcome | Effect Size | Evidence Level | Notes |
|-------|--------|------------|---|--------------|------------|-----------------|-------------|----------------|-------|
| DESTINY-Breast03 (CortÃ©s 2022) | RCT, Phase III | HER2+ mBC, 2L, æ—¢å¾€T/Pæ²»ç–— | 524 (261 vs 263) | T-DXd 5.4mg/kg q3w | T-DM1 3.6mg/kg q3w | PFS (BICR) | mPFS: 28.8m vs 6.8m<br>HR 0.33 (0.26-0.43, p<0.001) | Level 1 | ORR: 79.7% vs 34.2%<br>è„‘è½¬ç§»äºšç»„HR 0.25<br>Gradeâ‰¥3 AE: 45% vs 39% |
| DESTINY-Breast01 (Modi 2020) | Single-arm Phase II | HER2+ mBC, 3L+, æ—¢å¾€T-DM1 | 184 | T-DXd 5.4mg/kg q3w | N/A | ORR (BICR) | ORR: 60.9% (53.4-68.0)<br>mPFS: 16.4m | Level 2 | DOR: 14.8m<br>ILDå‘ç”Ÿç‡: 13.6% (Gradeâ‰¥3: 2.7%) |
| HER2CLIMB (Murthy 2020) | RCT, Phase II | HER2+ mBC with brain mets, 2L+ | 612 (410 vs 202) | Tucatinib + Cap + T | Placebo + Cap + T | PFS (ITT) | mPFS: 7.8m vs 5.6m<br>HR 0.54 (0.42-0.71, p<0.00001) | Level 1 | CNS-PFS: 9.9m vs 4.2m (HR 0.32)<br>è…¹æ³» Gradeâ‰¥3: 13% |

### ç¤ºä¾‹2: EGFR-TKIä¸€çº¿æ²»ç–—æ¯”è¾ƒï¼ˆNSCLCï¼‰

| Study | Design | Population | N | Intervention | Comparator | Primary Outcome | Effect Size | Evidence Level | Notes |
|-------|--------|------------|---|--------------|------------|-----------------|-------------|----------------|-------|
| FLAURA (Soria 2018) | RCT, Phase III | EGFR mut NSCLC, 1L | 556 (279 vs 277) | Osimertinib 80mg QD | Gefitinib/Erlotinib | PFS (INV) | mPFS: 18.9m vs 10.2m<br>HR 0.46 (0.37-0.57, p<0.001) | Level 1 | CNS-PFS: NR vs 13.9m (HR 0.48)<br>OS: 38.6m vs 31.8m (HR 0.80, p=0.046) |
| ARCHER 1050 (Wu 2020) | RCT, Phase III | EGFR exon19del NSCLC, 1L | 452 (226 vs 226) | Dacomitinib 45mg QD | Gefitinib 250mg QD | PFS (BICR) | mPFS: 14.7m vs 9.2m<br>HR 0.59 (0.47-0.74, p<0.001) | Level 1 | OS: 34.1m vs 27.0m (HR 0.76, p=0.044)<br>çš®ç–¹/è…¹æ³»æ›´å¸¸è§ï¼Œéœ€dose adjustment |

---

## ğŸ” è´¨é‡æ£€æŸ¥æ¸…å•

å¡«è¡¨å®Œæˆåï¼Œç¡®è®¤ä»¥ä¸‹è¦ç‚¹ï¼š

- [ ] **å®Œæ•´æ€§**: æ‰€æœ‰å…³é”®åˆ—éƒ½å·²å¡«å†™ï¼ˆè‡³å°‘åŒ…å«Study, N, Intervention, Primary Outcome, Effect Sizeï¼‰
- [ ] **ä¸€è‡´æ€§**: æ•ˆåº”é‡çš„è¡¨è¾¾æ ¼å¼ç»Ÿä¸€ï¼ˆå¦‚éƒ½ç”¨HR + 95%CIï¼‰
- [ ] **å‡†ç¡®æ€§**: æ•°å­—ç›´æ¥æ¥è‡ªåŸæ–‡ï¼Œæœªè¿›è¡Œå››èˆäº”å…¥æˆ–ä¼°ç®—
- [ ] **å¯æ¯”æ€§**: å¦‚æœæ˜¯æ¯”è¾ƒå¤šä¸ªç ”ç©¶ï¼Œæ‚£è€…ç¾¤ä½“å’Œç»ˆç‚¹å®šä¹‰å¯æ¯”
- [ ] **é€æ˜æ€§**: Notesåˆ—æ ‡æ³¨äº†é‡è¦çš„å¼‚è´¨æ€§æ¥æºæˆ–ç ”ç©¶å±€é™

---

## ğŸ“Œ é«˜çº§ç”¨æ³•

### ç”¨æ³•1: åˆ†å±‚å±•ç¤ºï¼ˆæŒ‰è¯æ®ç­‰çº§ï¼‰

**Level 1 Evidence (High-quality RCTs)**

| Study | ... | Effect Size | Notes |
|-------|-----|-------------|-------|
| ... | ... | ... | ... |

**Level 2 Evidence (Lower-quality RCTs / High-quality observational)**

| Study | ... | Effect Size | Notes |
|-------|-----|-------------|-------|
| ... | ... | ... | ... |

### ç”¨æ³•2: æŒ‰äºšç»„åˆ†å±‚

**Overall Population**

| Study | ... | Effect Size | Notes |
|-------|-----|-------------|-------|
| ... | ... | ... | ... |

**Subgroup: Brain Metastases**

| Study | ... | Effect Size | Notes |
|-------|-----|-------------|-------|
| ... | ... | ... | ... |

### ç”¨æ³•3: æ•´åˆå®‰å…¨æ€§æ•°æ®

åœ¨ä¸»è¡¨åæ·»åŠ å®‰å…¨æ€§æ±‡æ€»è¡¨ï¼š

**Safety Summary**

| Study | Grade â‰¥3 AE (%) | Treatment Discontinuation (%) | Common AEs (Grade â‰¥3) | Special Warnings |
|-------|-----------------|-------------------------------|----------------------|------------------|
| ... | 45% | 15% | ä¸­æ€§ç²’ç»†èƒå‡å°‘(20%), æ¶å¿ƒ(8%) | ILDé£é™© (13.6%) |

---

## ğŸ¯ è¾“å‡ºå»ºè®®

**åœ¨æŠ¥å‘Šä¸­çš„ä½¿ç”¨**:

1. **æ”¾ç½®ä½ç½®**: é€šå¸¸åœ¨"Evidence Summary"æˆ–"Results"ç« èŠ‚
2. **é…åˆæ–‡å­—**: è¡¨æ ¼å‰ç”¨1-2æ®µæ–‡å­—ä»‹ç»ç ”ç©¶æ£€ç´¢ç­–ç•¥å’Œçº³å…¥æ ‡å‡†
3. **è¡¨æ ¼ååˆ†æ**: è¡¨æ ¼åç”¨æ–‡å­—æ€»ç»“å…³é”®å‘ç°ã€å¼‚è´¨æ€§å’Œè¯æ®è´¨é‡
4. **å¯è§†åŒ–**: å¦‚æœ‰æ¡ä»¶ï¼Œå¯å°†å…³é”®æ•°æ®è½¬åŒ–ä¸ºæ£®æ—å›¾æˆ–æ°”æ³¡å›¾

**ç¤ºä¾‹æ–‡å­—ï¼ˆè¡¨æ ¼å‰ï¼‰**:
```markdown
## Evidence Summary

We conducted a systematic search of PubMed, Embase, and ClinicalTrials.gov
(search date: 2025-12-07) using the terms "HER2-positive breast cancer" AND
"trastuzumab deruxtecan" OR "T-DXd". Studies were included if they reported
efficacy outcomes in patients with HER2+ metastatic breast cancer previously
treated with trastuzumab-based therapy.

**Search Results**: 156 articles identified â†’ 45 full-text reviewed â†’ 3 key studies included

The following table summarizes the key evidence:

[æ’å…¥è¡¨æ ¼]

**Key Findings**: ...
```

---

*Template Version: 1.0*
*Last Updated: 2025-12-07*
*Part of: Medical Research Analyst Skill - LiYe OS*
